November 17, 2020

Andrew Rackear Chief Executive Officer and Secretary Enzon Pharmaceuticals, Inc. 20 Commerce Drive (Suite 135) Cranford, NJ 07016

Re: Enzon

Pharmaceuticals, Inc.

Statement on Form S-1

Registration

Filed November 12,

2020

File No. 333-250031

Dear Mr. Rackear:

This is to advise you that we have not reviewed and will not review your registration statement.

 $\,$ Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you

that the company and its management are responsible for the accuracy and adequacy of their $\,$

disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact David

Gessert at 202-551-2326 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences